
Aytu BioScience (AYTU) Stock Forecast & Price Target
Aytu BioScience (AYTU) Analyst Ratings
Bulls say
Aytu BioPharma Inc. possesses an attractive current valuation supported by a net present value (NPV) analysis, indicating significant upside potential from its current share price. Additionally, the company is anticipating a strong market entry for its new EXXUA drug, targeting major depressive disorder (MDD) in Q4 2025, which is expected to serve as a key catalyst for future stock performance. The successful clinical outcomes of EXXUA, including its ability to improve depression symptoms while minimizing common side effects, further enhance the company's growth prospects in a competitive therapeutic landscape.
Bears say
Aytu BioPharma's stock is currently trading significantly below projections of future sales, indicating potential valuation concerns. Despite the noted growth prospects and the significant unmet needs in the antidepressant market, the company faces high risks that may overshadow these opportunities. Additionally, the reliance on third-party sales for its prescription pharmaceutical products raises uncertainties regarding revenue stability in a competitive landscape.
This aggregate rating is based on analysts' research of Aytu BioScience and is not a guaranteed prediction by Public.com or investment advice.
Aytu BioScience (AYTU) Analyst Forecast & Price Prediction
Start investing in Aytu BioScience (AYTU)
Order type
Buy in
Order amount
Est. shares
0 shares